Biotechnology grows and finds alternative forms of financing
30/06/2015
Diego Gutiérrez
Biotechnology grows and finds alternative forms of financing
According to Asebio, the number of healthcare biotechnology projects developed in Spain grew by 30% in 2015, compared to the same period in 2014. These projects need funding and many of them are turning to alternative financing. Crowdfunding, public aid and venture capital funds are helping to make Spain a biotech country.

 

 

Zeclinics receives funding through crowdfunding

The Catalan company ZeClinics, born at the Pompeu Fabra University in Barcelona, haddeveloped a test to personalise cancer treatment with chemotherapy based on xenotransplantation in zebrafish embryos.
In order to develop its new product, ZeClinics decided to crowdfund through the crowdfunding platform Capital Cell. 88 days into the campaign, the company has raised €100,000.

"Capital cell is a crowdequity platform that supports entrepreneurs in the health sector in exchange for a stake in the company. The platform, which was created in early 2015, is one of the pioneers focused solely on the healthcare sector. The investment in Zeclinics is the second one made in the platform after Iproteos to raise another €100,000," says Diego Gutierrez of Abra-Invest.

 

New venture capital funds

In addition to the programme CaixImpulse, as we discussed in a post last week, the Botín Foundation also intends to reform its commitment to the sector.

Thanks to CaixImpulse, 15 projects in the field of health will receive the necessary financial support for the preparation and implementation of their value creation and marketing plans for their assets.

The Botín Foundation is working on the creation of a fund to attract external capital and place it in the biotech sector. The fund, which is expected to be set up before the end of the year, will have a minority shareholding from the Foundation.

 

Biotech companies that have received support from H2020

Companies such as Oxcta and Proalt have recently received funding from Europe through the SME instrument phase II.
Oxcta is a biosecurity company located in the Huesca technology park.

Proalt is a biomarker company for various pathologies, especially in cancer.

 If you are looking for public or private financing, we are happy to help you. Contact us on +34.946024142

Lastest news

Últimas transacciones del sector Cybersecurity

El sector de la ciberseguridad ha sido testigo de una importante oleada de adquisiciones estratégicas en los últimos meses, a medida que las empresas tratan de ampliar sus capacidades y hacer frente a la creciente demanda de una sólida protección digital. Cinco...

Latest transactions in the Consumer Software sector

El sector del Consumer software ha experimentado recientemente una dinámica oleada de adquisiciones que pone de relieve su evolución hacia la mejora de la participación de los usuarios y la ampliación de los servicios digitales. Entre las operaciones más destacadas...

Latest transactions in the Industrial Tech sector

El sector de la tecnología industrial ha sido testigo de una oleada de transacciones estratégicas en los últimos meses, señal de una rápida evolución y expansión. Entre las operaciones más destacadas, Bosch Energy and Building Solutions adquirió DMS Ettlingen para...

Do you want to sell or buy a company?

We are experts in M&A transactions in the technology sector.

Subscribe to our newsletter

Request for information

If you want to buy or sell a company, or need more information about our services, do not hesitate to contact us through the form.

Or if you prefer, call us at:

+34 946 42 41 42